The Inflation Reduction Act

The Inflation Reduction Act of 2022 is a landmark United States federal law which aims to curb inflation by, among other things, lowering prescription drug prices. What can this mean for biopharmaceutical companies?Dennis Kim, Senior Engagement Manager and Em Coriale, Director in the Value & Access team at Syneos Health, dive into the details of this piece of legislation, the true meaning of “unjustified price increases,” what negotiation might look like and how companies can prepare for the new reality.   For additional insights on the Inflation Reduction Act from our Reputation & Risk Management team, visit our blog.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].